参考文献/References:
[1] Poget M,Fresa M,El Ezzi O,et al.Lymphatic malformations in children:retrospective review of surgical and interventional management[J].Pediatr Surg Int,2022,39:36.
[2]Schoinohoriti OK,Theologie-Lygidakis N,Tzerbos F,et al.Lymphatic malformations in children and adolescents[J].J Craniofac Surg,2012,23:1744-1747.
[3]吴 江,黄庆荣,汪根树,等.小儿淋巴管瘤病理性质的探讨[J].中华小儿外科杂志,2002,23:568-569.
[4]Osborn AJ,Dickie P,Neilson DE,et al.Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations[J].Hum Mol Genet,2015,24:926-938.
[5]Blesinger H,KaulfuB S,Aung T,et al.PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations[J].PLoS One,2018,13:e0200343.
[6]Zenner K,Cheng CV,Jensen DM,et al.Genotype correlates with clinical severity in PIK3CA-associated lymphatic malformations[J].JCI Insight,2019,4:e129884.
[7]Luks VL,Kamitaki N,Vivero MP,et al.Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA[J].J Pediatr,2015,166:1048-1054.e1-5.
[8]Ichise T,Yoshida N,Ichise H.H-,N- and Kras cooperatively regulate lymphatic vessel growth by modulating VEGFR3 expression in lymphatic endothelial cells in mice[J].Development,2010,137:1003-1013.
[9]Hominick D,Silva A,Khurana N,et al.VEGF-C promotes the development of lymphatics in bone and bone loss[J].Elife,2018,7:e34323.
[10]张 丹.血清外泌体miR-202-3p介导内皮细胞损伤在主动脉夹层发病中的作用及机制研究[D].新疆:新疆医科大学,2024.
[11]Han T,Yan J,Chen H,et al.HIF-1α contributes to tube malformation of human lymphatic endothelial cells by upregulating VEGFR-3[J].Int J Oncol,2019,54:139-151.
[12]中华医学会整形外科分会血管瘤脉管畸形学组.血管瘤与脉管畸形诊治指南(2024版)[J].组织工程与重建外科杂志,2024,20:1-50.
[13]Perkins JA,Manning SC,Tempero RM,et al.Lymphatic malformations:current cellular and clinical investigations[J].Otolaryngol Head Neck Surg,2010,142:789-794.
[14]Friedman SL,Neuschwander-Tetri BA,Rinella M,et al.Mechanisms of NAFLD development and therapeutic strategies[J].Nat Med,2018,24:908-922.
[15]Wassef M,Blei F,Adams D,et al.Vascular Anomalies Classification:Recommendations From the International Society for the Study of Vascular Anomalies[J].Pediatrics,2015,136:e203-214.
[16]Hill RH 3rd,Shiels WE 2nd,Foster JA,et al.Percutaneous drainage and ablation as first line therapy for macrocystic and microcystic orbital lymphatic malformations[J].Ophthalmic Plast Reconstr Surg,2012,28:119-125.
[17]Wiegand S,Wichmann G,Dietz A,et al.Association between malformation type,location and functional deficits in lymphatic malformations of the head and neck in children[J].Eur Arch Otorhinolaryngol,2023,280:2535-2540.
[18]贾玉林,赵怡芳.舌下腺囊肿的诊断与鉴别诊断[J].中国实用口腔科杂志,2019,12:65-68.
[19]王德明,苏立新,范新东.静脉畸形中国专家共识[J].介入放射学杂志,2019,28:307-311.
[20]Parashar G,Shankar G,Sahadev R,et al.Intralesional Sclerotherapy with bleomycin in lymphatic malformation of tongue an institutional experience and outcomes[J].J Indian Assoc Pediatr Surg,2020,25:80-84.
[21]Honnorat M,Viremouneix L,Ayari S,et al.Early adjuvant medication with the mTOR inhibitor sirolimus in a preterm neonate with compressive cystic lymphatic malformation[J].Front Pediatr,2020,8:418.
[22]Giacalone G,Yamamoto T,Belva F,et al.The application of virtual reality for preoperative planning of lymphovenous anastomosis in a patient with a complex lymphatic malformation[J].J Clin Med,2019,8:371.
[23]李 洁,郑明明.产前图像学和遗传学筛查与诊断工作常规[M].江苏科学技术出版社,2023.
[24]Fernandes S,Yeung P,Heran M,et al.Sclerosing agents in the management of lymphatic malformations in children:a systematic review[J].J Pediatr Surg,2022,57:888-896.
[25]Sun J,Wang C,Li J,et al.The efficacy of bleomycin sclerotherapy in the treatment of lymphatic malformations:a review and meta-analysis[J].Braz J Otorhinolaryngol,2023,89:101285.
[26]Chaudry G,Guevara CJ,Rialon KL,et al.Safety and efficacy of bleomycin sclerotherapy for microcystic lymphatic malformation[J].Cardiovasc Intervent Radiol,2014,37:1476-1481.
[27]Bhatnagar A,Upadhyaya VD,Kumar B,et al.Aqueous intralesional bleomycin sclerotherapy in lymphatic malformation:Our experience with children and adult[J].Natl J Maxillofac Surg,2017,8:130-135.
[28]劳永浩,李 龙.博莱霉素类药物硬化疗法在囊肿性疾病中的应用[J].介入放射学杂志,2019,28:92-97.
[29]中华口腔医学会口腔颌面外科专业委员会脉管性疾病学组.平阳霉素治疗脉管性疾病规范[J].中国口腔颌面外科杂志,2011,9:68-69.
[30]赵冉冉,李晨曦,热孜万古丽·亚森,等.负压封闭引流在颌面颈部间隙感染致下行性坏死性纵隔炎治疗中的应用效果评价[J].中国口腔颌面外科杂志,2024,22:153-157.
[31]中华口腔医学会口腔颌面外科专业委员会脉管性疾病学组.聚桂醇硬化剂治疗口腔颌面部血管瘤和脉管畸形专家共识[J].中国口腔颌面外科杂志,2018,16:275-278.
[32]中国微循环学会周围血管疾病专业委员会血管瘤与脉管畸形专家委员会,中国医师协会介入医师分会妇儿介入学组,中国血管瘤血管畸形协作网,等.聚多卡醇硬化治疗血管瘤与脉管畸形中国专家共识[J].血管与腔内血管外科杂志,2023,9:1281-1287.
[33]Yamaki T,Sasaki Y,Hasegawa Y,et al.Percutaneous ultrasound-guided sclerotherapy with polidocanol microfoam for lymphatic malformations[J].J Vasc Surg Venous Lymphat Disord,2017,5:707-714.
[34]宋 丹,郭 磊,王 亮,等.超声引导下经皮注射聚桂醇泡沫硬化剂治疗儿童淋巴管畸形的临床疗效及安全性分析[J].医学影像学杂志,2024,34:108-111.
[35]Tessari L,Cavezzi A,Frullini A.Preliminary experience with a new sclerosing foam in the treatment of varicose veins[J].Dermatol Surg,2001,27:58-60.
[36]Impellizzeri P,Romeo C,Borruto FA,et al.Sclerotherapy for cervical cystic lymphatic malformations in children.Our experience with computed tomography-guided 98% sterile ethanol insertion and a review of the literature[J].J Pediatr Surg,2010,45:2473-2478.
[37]Gilat EK,Cohen I,Brin D,et al.A 14-year single-center experience evaluating sclerotherapy efficacy in lymphatic malformations[J].J Vasc Surg Venous Lymphat Disord,2024,12:101938.
[38]韩一峰,范新东.无水乙醇介入治疗头颈部囊性病变的临床应用现状[J].中国口腔颌面外科杂志,2015,13:187-189.
[39]Fernandes S,Yeung P,Heran M,et al.Sclerosing agents in the management of lymphatic malformations in children:a systematic review[J].J Pediatr Surg,2022,57:888-896.
[40]Sun J,Wang C,Song D,et al.Efficacy of OK-432 sclerotherapy for different types of lymphangiomas:a review and meta-analysis[J].Braz J Otorhinolaryngol,2023,89:101270.
[41]Molitch HI,Unger EC,Witte CL,et al.Percutaneous sclerotherapy of lymphangiomas[J].Radiology,1995,194:343-347.
[42]Shaye DA,Burks CA,Gadkaree SK,et al.Self-compounded doxycycline sclerotherapy for the treatment of lymphatic malformations in low-resource settings[J].World J Surg,2020,44:3616-3619.
[43]时 豪,吕志宝,陈 舟.多西环素注射治疗儿童大囊型和混合型囊性淋巴管畸形的疗效与安全性探讨[J].临床小儿外科杂志,2022,21:558-561.
[44]July J,Peeters S.Preoperative intralesional injection of triamcinolone acetonide for a large head and neck lymphangioma in a baby:a case report[J].Paediatrica Indonesiana,2018,57:274-278.
[45]Luo QF,Gan YH.Pingyangmycin with triamcinolone acetonide effective for treatment of lymphatic malformations in the oral and maxillofacial region[J].J Craniomaxillofac Surg,2013,41:345-349.
[46]邰茂众,陈 涛,李克雷,等.2种病变内平阳霉素注射方法治疗68例儿童唇面部微囊型淋巴管畸形疗效分析[J].中国口腔颌面外科杂志,2022,20:268-272.
[47]宋 丹,郭 磊,李 静,等.聚桂醇腔内灌洗联合低浓度平阳霉素治疗儿童大囊型淋巴管畸形的临床观察[J].中华整形外科杂志,2020,36:392-397.
[48]陈昆山,张 靖,申 刚,等.猪尾引流导管在淋巴管畸形硬化治疗中的应用及疗效分析[J].介入放射学杂志,2016,25:106-110.
[49]王延安,秦中平,郑家伟,等.头颈部血管瘤及脉管畸形手术治疗专家共识[J].中国口腔颌面外科杂志,2024,22:105-117.
[50]Lisan Q,Villepelet A,Parodi M,et al.Value of radiofrequency ablation in the management of retropharyngeal lymphatic malformation[J].Int J Pediatr Otorhinolaryngol,2016,83:37-40.
[51]Khurana A,Gupta A,Ahuja A,et al.Lymphangioma circumscriptum treated with combination of bleomycin sclerotherapy and radiofrequency ablation[J].J Cosmet Laser Ther,2018,20:326-329.
[52]Shumaker PR,Dela Rosa KM,Krakowski AC.Treatment of lymphangioma circumscriptum using fractional carbon dioxide laser ablation[J].Pediatr Dermatol,2013,30:584-586.
[53]Kim SW,Kavanagh K,Orbach DB,et al.Long-term outcome of radiofrequency ablation for intraoral microcystic lymphatic malformation[J].Arch Otolaryngol Head Neck Surg,2011,137:1247-1250.
[54]Thottam PJ,Al-Barazi R,Madgy DN,et al.Submucosal resection of a microcystic oropharyngeal lymphatic malformation using radiofrequency ablation[J].Int J Pediatr Otorhinolaryngol,2013,77:1589-1592.
[55]Teng J,Hammill A,Martini J,et al.Sirolimus in the treatment of microcystic lymphatic malformations:a systematic review[J].Lymphat Res Biol,2023,21:101-110.
[56]Wu C,Song D,Guo L,et al.Refractory head and neck lymphatic malformation in infants treated with sirolimus:a case series[J].Front Oncol,2021,11:616702.
[57]孔亮亮,韩 涛,高庆文,等.口服西罗莫司治疗难治性脉管性疾病的有效性与安全性[J].中华整形外科杂志,2020,36:487-493.
[58]Freixo C,Ferreira V,Martins J,et al.Efficacy and safety of sirolimus in the treatment of vascular anomalies:a systematic review[J].J Vasc Surg,2020,71:318-327.
(收稿日期:2025-01-23)
(本文编辑:谷 珂)